Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Brentuximabe Vedotin e Nivolumabe com ou sem Ipilimumabe no tratamento de pacientes com linfoma de Hodgkin recidivante ou refratário

11 de novembro de 2026 atualizado por: National Cancer Institute (NCI)

Um estudo de Fase I com uma Coorte de Expansão/Estudo Randomizado de Fase II das Combinações de Ipilimumabe, Nivolumabe e Brentuximabe Vedotin em Pacientes com Linfoma de Hodgkin Recidivante/Refratário

This phase I/II trial studies the side effects and best dose of ipilimumab and nivolumab when given together with brentuximab vedotin, and how well they work in treating patients with Hodgkin lymphoma that has returned after a period of improvement (recurrent) or has not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. It is not known whether giving brentuximab vedotin and nivolumab with or without ipilimumab may kill more cancer cells.

Visão geral do estudo

Descrição detalhada

PRIMARY OBJECTIVES:

I. To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of the combinations of brentuximab vedotin and ipilimumab, brentuximab vedotin and nivolumab, and brentuximab vedotin, ipilimumab, and nivolumab. (Phase I) II. To evaluate the complete response (CR) rate for the regimens of brentuximab vedotin and nivolumab compared to brentuximab vedotin, ipilimumab, and nivolumab. (Phase II; adult cohort [aged >= 18 years]) III. To characterize the safety and toxicity of treatment combination in the pediatric population. (Phase II; pediatric cohort [aged 12-17 years])

SECONDARY OBJECTIVES:

I. To evaluate complete response (CR) rate, partial response (PR) rate and overall response rate (ORR), for the combinations of brentuximab vedotin and ipilimumab, brentuximab vedotin and nivolumab, and brentuximab vedotin, ipilimumab, and nivolumab. (Phase I) II. To evaluate the duration of remission (DOR) to these combinations and compare with the DOR achieved with the most recent prior systemic therapy. (Phase I) III. To evaluate the progression-free survival (PFS) and the overall survival (OS) in patients receiving the combination of brentuximab vedotin and ipilimumab, brentuximab vedotin and nivolumab, and brentuximab vedotin, ipilimumab, and nivolumab. (Phase I) IV. To evaluate the ORR, PR, and stable disease (SD) rate for the combinations of brentuximab vedotin and nivolumab and brentuximab vedotin, ipilimumab, and nivolumab. (Phase II) V. To evaluate the DOR to these combinations and compare with the DOR achieved with the most recent prior systemic therapy. (Phase II) VI. To evaluate the 5 year PFS and OS in patients receiving the combinations of brentuximab vedotin and nivolumab and brentuximab vedotin, ipilimumab, and nivolumab. (Phase II) VII. To further evaluate the safety and characterize the toxicity for the combinations of brentuximab vedotin and nivolumab, and brentuximab vedotin, ipilimumab, and nivolumab. (Phase II)

CORRELATIVE STUDY OBJECTIVES:

I. To evaluate the ability of these combinations to alter tumor specific T cell immunity. (Phase I) II. To evaluate the effects of these combinations on systemic immunity. (Phase I) III. To evaluate a panel of cytokine and T cell specific biomarkers from the peripheral blood as a potential immune signature of treatment response to therapy with these combinations for patients with relapsed/refractory Hodgkin lymphoma (HL). (Phase I) IV. To evaluate using gene expression profiling (GEP) a signature of response to these novel combinations of an antibody drug conjugate with immunomodulatory therapy. (Phase I) V. To evaluate the ability of these combinations to alter tumor specific T cell immunity, and circulating T cell phenotypes, in patients as a function of treatment response at multiple timepoints during therapy. (Phase II) VI. To evaluate peripheral blood cytokine profiles in responding and resistant patients at multiple timepoints during therapy. (Phase II) VII. To evaluate using GEP a signature of response versus (vs.) resistance to these novel combinations of an antibody drug conjugate with immunomodulatory therapy. (Phase II) VIII. To evaluate the influence of human gut microbiome dysbiosis on HL lymphomagenesis and the systemic immune response. (Phase II)

IMAGING CORRELATIVE STUDY OBJECTIVES:

I. To evaluate atypical response patterns with currently available response evaluation criteria. (Phase II) II. To correlate response evaluated using currently available response evaluation criteria with duration of response (PFS, event free survival [EFS], failure free survival [FFS]). (Phase II) III. To evaluate response patterns in different immunotherapy treatment schemes and correlate with historical data using chemotherapy. (Phase II) IV. To correlate imaging changes in all treatment schemes quantitatively with PFS. (Phase II)

EXPLORATORY OBJECTIVES:

I. Evaluate outcomes (CR, PFS) between patients with/without prior transplants. (Phase II) II. Evaluate outcomes (PFS, OS) between the patients who stay on treatment and do not go to transplant in both arms (the post auto and the few others who don't want transplant) vs the patients who go off for transplant. (Phase II) III. Evaluate outcomes (CR, PFS) in pediatric population (age 12 to < 18 years of age) vs. adult population. (Phase II)

OUTLINE: This is a phase I, dose-escalation study of brentuximab vedotin, ipilimumab, and nivolumab followed by a phase II study.

PHASE I: Patients are assigned into 1 of 3 arms.

ARM I: Patients receive brentuximab vedotin intravenously (IV) over 90 minutes on day 1 of cycles 1-16 and ipilimumab IV over 30 minutes on day 1 of cycles 1-4, 8, 12, and 16. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16 and nivolumab IV over 30 minutes on day 1 of cycles 1-46. Treatment repeats every 21 days for up to 16 cycles and every 14 days beginning cycle 17 for up to 46 cycles in the absence of disease progression or unacceptable toxicity.

ARM III: Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16, nivolumab IV over 30 minutes on day 1 of cycles 1-46, and ipilimumab IV over 30 minutes on day 1 every 12 weeks for up to 9 doses. Treatment repeats every 21 days for up to 16 cycles and every 14 days beginning cycle 17 for up to 46 cycles in the absence of disease progression or unacceptable toxicity.

PHASE II: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive brentuximab vedotin IV over 30 minutes on day 1 of cycles 1-16 and nivolumab IV over 90 minutes on day 1 of cycles 1-34. Treatment repeats every 21 days for up to 34 cycles in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16, nivolumab IV over 30 minutes on day 1 of cycles 1-34, and ipilimumab IV over 30 minutes on day 1 every 12 weeks for up to 9 doses. Treatment repeats every 21 days for up to 34 cycles in the absence of disease progression or unacceptable toxicity.

All patients also undergo computed tomography (CT) or positron emission tomography (PET) scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study.

After completion of phase I study treatment, patients are followed up every 3 months for 1 year, then every 6 months for 2 years. After completion of phase II study treatment, patients are followed up for 10 years.

Tipo de estudo

Intervencional

Inscrição (Estimado)

146

Estágio

  • Fase 2
  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Alabama
      • Birmingham, Alabama, Estados Unidos, 35233
        • University of Alabama at Birmingham Cancer Center
      • Birmingham, Alabama, Estados Unidos, 35233
        • Children's Hospital of Alabama
    • Alaska
      • Anchorage, Alaska, Estados Unidos, 98508
        • Anchorage Associates in Radiation Medicine
      • Anchorage, Alaska, Estados Unidos, 99508
        • Alaska Breast Care and Surgery LLC
      • Anchorage, Alaska, Estados Unidos, 99508
        • Alaska Oncology and Hematology LLC
      • Anchorage, Alaska, Estados Unidos, 99508
        • Alaska Women's Cancer Care
      • Anchorage, Alaska, Estados Unidos, 99508
        • Anchorage Oncology Centre
      • Anchorage, Alaska, Estados Unidos, 99508
        • Katmai Oncology Group
      • Anchorage, Alaska, Estados Unidos, 99508
        • Providence Alaska Medical Center
      • Anchorage, Alaska, Estados Unidos, 99504
        • Anchorage Radiation Therapy Center
      • Fairbanks, Alaska, Estados Unidos, 99701
        • Fairbanks Memorial Hospital
    • Arizona
      • Kingman, Arizona, Estados Unidos, 86401
        • Kingman Regional Medical Center
      • Phoenix, Arizona, Estados Unidos, 85004
        • Cancer Center at Saint Joseph's
    • Arkansas
      • Fort Smith, Arkansas, Estados Unidos, 72903
        • Mercy Hospital Fort Smith
      • Hot Springs, Arkansas, Estados Unidos, 71913
        • CHI Saint Vincent Cancer Center Hot Springs
    • California
      • Antioch, California, Estados Unidos, 94531
        • Kaiser Permanente-Deer Valley Medical Center
      • Arroyo Grande, California, Estados Unidos, 93420
        • PCR Oncology
      • Arroyo Grande, California, Estados Unidos, 93420
        • Mission Hope Medical Oncology - Arroyo Grande
      • Burbank, California, Estados Unidos, 91505
        • Providence Saint Joseph Medical Center/Disney Family Cancer Center
      • Dublin, California, Estados Unidos, 94568
        • Kaiser Permanente Dublin
      • Fremont, California, Estados Unidos, 94538
        • Kaiser Permanente-Fremont
      • Fresno, California, Estados Unidos, 93720
        • Kaiser Permanente-Fresno
      • Fresno, California, Estados Unidos, 93720
        • Fresno Cancer Center
      • Modesto, California, Estados Unidos, 95356
        • Kaiser Permanente-Modesto
      • Oakland, California, Estados Unidos, 94611
        • Kaiser Permanente-Oakland
      • Oakland, California, Estados Unidos, 94611
        • Kaiser Permanente Oakland-Broadway
      • Orange, California, Estados Unidos, 92868
        • Children's Hospital of Orange County
      • Palo Alto, California, Estados Unidos, 94304
        • Stanford Cancer Institute Palo Alto
      • Rancho Cordova, California, Estados Unidos, 95670
        • Kaiser Permanente-Rancho Cordova Cancer Center
      • Redwood City, California, Estados Unidos, 94063
        • Kaiser Permanente-Redwood City
      • Richmond, California, Estados Unidos, 94801
        • Kaiser Permanente-Richmond
      • Rohnert Park, California, Estados Unidos, 94928
        • Rohnert Park Cancer Center
      • Roseville, California, Estados Unidos, 95678
        • The Permanente Medical Group-Roseville Radiation Oncology
      • Roseville, California, Estados Unidos, 95661
        • Kaiser Permanente-Roseville
      • Sacramento, California, Estados Unidos, 95814
        • Kaiser Permanente Downtown Commons
      • Sacramento, California, Estados Unidos, 95823
        • Kaiser Permanente-South Sacramento
      • Sacramento, California, Estados Unidos, 95823
        • South Sacramento Cancer Center
      • Sacramento, California, Estados Unidos, 95825
        • Kaiser Permanente Sacramento Medical Center
      • San Francisco, California, Estados Unidos, 94115
        • Kaiser Permanente-San Francisco
      • San Francisco, California, Estados Unidos, 94158
        • UCSF Medical Center-Mission Bay
      • San Jose, California, Estados Unidos, 95119
        • Kaiser Permanente-Santa Teresa-San Jose
      • San Leandro, California, Estados Unidos, 94577
        • Kaiser Permanente San Leandro
      • San Luis Obispo, California, Estados Unidos, 93401
        • Pacific Central Coast Health Center-San Luis Obispo
      • San Rafael, California, Estados Unidos, 94903
        • Kaiser San Rafael-Gallinas
      • San Rafael, California, Estados Unidos, 94903
        • Kaiser Permanente-San Rafael
      • Santa Clara, California, Estados Unidos, 95051
        • Kaiser Permanente Medical Center - Santa Clara
      • Santa Maria, California, Estados Unidos, 93444
        • Mission Hope Medical Oncology - Santa Maria
      • Santa Rosa, California, Estados Unidos, 95403
        • Kaiser Permanente-Santa Rosa
      • South San Francisco, California, Estados Unidos, 94080
        • Kaiser Permanente Cancer Treatment Center
      • South San Francisco, California, Estados Unidos, 94080
        • Kaiser Permanente-South San Francisco
      • Stockton, California, Estados Unidos, 95210
        • Kaiser Permanente-Stockton
      • Vacaville, California, Estados Unidos, 95688
        • Kaiser Permanente Medical Center-Vacaville
      • Vallejo, California, Estados Unidos, 94589
        • Kaiser Permanente-Vallejo
      • Walnut Creek, California, Estados Unidos, 94596
        • Kaiser Permanente-Walnut Creek
    • Colorado
      • Aurora, Colorado, Estados Unidos, 80012
        • Rocky Mountain Cancer Centers-Aurora
      • Aurora, Colorado, Estados Unidos, 80012
        • The Medical Center of Aurora
      • Boulder, Colorado, Estados Unidos, 80303
        • Boulder Community Foothills Hospital
      • Boulder, Colorado, Estados Unidos, 80304
        • Rocky Mountain Cancer Centers-Boulder
      • Centennial, Colorado, Estados Unidos, 80112
        • Rocky Mountain Cancer Centers - Centennial
      • Colorado Springs, Colorado, Estados Unidos, 80907
        • Penrose-Saint Francis Healthcare
      • Colorado Springs, Colorado, Estados Unidos, 80907
        • Rocky Mountain Cancer Centers-Penrose
      • Denver, Colorado, Estados Unidos, 80218
        • Presbyterian - Saint Lukes Medical Center - Health One
      • Denver, Colorado, Estados Unidos, 80218
        • Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
      • Denver, Colorado, Estados Unidos, 80220
        • Rose Medical Center
      • Denver, Colorado, Estados Unidos, 80218
        • Rocky Mountain Cancer Centers-Midtown
      • Denver, Colorado, Estados Unidos, 80220
        • Rocky Mountain Cancer Centers-Rose
      • Denver, Colorado, Estados Unidos, 80204
        • Denver Health Medical Center
      • Denver, Colorado, Estados Unidos, 80218
        • Colorado Blood Cancer Institute
      • Denver, Colorado, Estados Unidos, 80204
        • Cancer Center of Colorado at Sloan's Lake
      • Denver, Colorado, Estados Unidos, 80209
        • The Women's Imaging Center
      • Denver, Colorado, Estados Unidos, 80206
        • National Jewish Health-Main Campus
      • Denver, Colorado, Estados Unidos, 80220
        • Western Surgical Care
      • Denver, Colorado, Estados Unidos, 80218
        • Saint Joseph Hospital - Cancer Centers of Colorado
      • Denver, Colorado, Estados Unidos, 80210
        • AdventHealth Porter
      • Durango, Colorado, Estados Unidos, 81301
        • Mercy Medical Center
      • Durango, Colorado, Estados Unidos, 81301
        • CommonSpirit Cancer Center Mercy
      • Englewood, Colorado, Estados Unidos, 80113
        • Mountain Blue Cancer Care Center - Swedish
      • Englewood, Colorado, Estados Unidos, 80113
        • Swedish Medical Center
      • Englewood, Colorado, Estados Unidos, 80113
        • Rocky Mountain Cancer Centers - Swedish
      • Golden, Colorado, Estados Unidos, 80401
        • Mountain Blue Cancer Care Center
      • Golden, Colorado, Estados Unidos, 80401
        • National Jewish Health-Western Hematology Oncology
      • Grand Junction, Colorado, Estados Unidos, 81501
        • Saint Mary's Hospital and Regional Medical Center
      • Greeley, Colorado, Estados Unidos, 80631
        • Banner North Colorado Medical Center
      • Lafayette, Colorado, Estados Unidos, 80026
        • Good Samaritan Hospital - Cancer Centers of Colorado
      • Lakewood, Colorado, Estados Unidos, 80228
        • Rocky Mountain Cancer Centers-Lakewood
      • Lakewood, Colorado, Estados Unidos, 80228
        • CommonSpirit Saint Anthony Hospital Cancer Center
      • Littleton, Colorado, Estados Unidos, 80120
        • Rocky Mountain Cancer Centers-Littleton
      • Littleton, Colorado, Estados Unidos, 80122
        • AdventHealth Littleton
      • Lone Tree, Colorado, Estados Unidos, 80124
        • Sky Ridge Medical Center
      • Lone Tree, Colorado, Estados Unidos, 80124
        • Rocky Mountain Cancer Centers-Sky Ridge
      • Longmont, Colorado, Estados Unidos, 80501
        • Longmont United Hospital
      • Longmont, Colorado, Estados Unidos, 80501
        • Rocky Mountain Cancer Centers-Longmont
      • Loveland, Colorado, Estados Unidos, 80539
        • Banner North Colorado Medical Center - Loveland Campus
      • Parker, Colorado, Estados Unidos, 80138
        • Rocky Mountain Cancer Centers-Parker
      • Parker, Colorado, Estados Unidos, 80138
        • AdventHealth Parker
      • Pueblo, Colorado, Estados Unidos, 81008
        • Rocky Mountain Cancer Centers - Pueblo
      • Thornton, Colorado, Estados Unidos, 80260
        • Rocky Mountain Cancer Centers-Thornton
      • Thornton, Colorado, Estados Unidos, 80260
        • National Jewish Health-Northern Hematology Oncology
      • Wheat Ridge, Colorado, Estados Unidos, 80401
        • Intermountain Health Lutheran Hospital
    • District of Columbia
      • Washington D.C., District of Columbia, Estados Unidos, 20010
        • Children's National Medical Center
    • Florida
      • Fort Myers, Florida, Estados Unidos, 33905
        • Regional Cancer Center-Lee Memorial Health System
      • Fort Myers, Florida, Estados Unidos, 33908
        • Golisano Children's Hospital of Southwest Florida
      • St. Petersburg, Florida, Estados Unidos, 33701
        • Johns Hopkins All Children's Hospital
      • Tampa, Florida, Estados Unidos, 33606
        • Tampa General Hospital
      • Tampa, Florida, Estados Unidos, 33607
        • Saint Joseph's Hospital/Children's Hospital-Tampa
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30322
        • Emory University Hospital/Winship Cancer Institute
      • Atlanta, Georgia, Estados Unidos, 30329
        • Children's Healthcare of Atlanta - Arthur M Blank Hospital
    • Hawaii
      • Honolulu, Hawaii, Estados Unidos, 96819
        • Kaiser Permanente Moanalua Medical Center
    • Idaho
      • Boise, Idaho, Estados Unidos, 83706
        • Saint Alphonsus Cancer Care Center-Boise
      • Boise, Idaho, Estados Unidos, 83712
        • Saint Luke's Cancer Institute - Boise
      • Caldwell, Idaho, Estados Unidos, 83605
        • Saint Alphonsus Cancer Care Center-Caldwell
      • Coeur d'Alene, Idaho, Estados Unidos, 83814
        • Kootenai Health - Coeur d'Alene
      • Emmett, Idaho, Estados Unidos, 83617
        • Walter Knox Memorial Hospital
      • Fruitland, Idaho, Estados Unidos, 83619
        • Saint Luke's Cancer Institute - Fruitland
      • Meridian, Idaho, Estados Unidos, 83642
        • Idaho Urologic Institute-Meridian
      • Meridian, Idaho, Estados Unidos, 83642
        • Saint Luke's Cancer Institute - Meridian
      • Nampa, Idaho, Estados Unidos, 83687
        • Saint Alphonsus Cancer Care Center-Nampa
      • Nampa, Idaho, Estados Unidos, 83687
        • Saint Luke's Cancer Institute - Nampa
      • Post Falls, Idaho, Estados Unidos, 83854
        • Kootenai Clinic Cancer Services - Post Falls
      • Sandpoint, Idaho, Estados Unidos, 83864
        • Kootenai Clinic Cancer Services - Sandpoint
      • Twin Falls, Idaho, Estados Unidos, 83301
        • Saint Luke's Cancer Institute - Twin Falls
    • Illinois
      • Alton, Illinois, Estados Unidos, 62002
        • OSF Saint Anthony's Health Center
      • Aurora, Illinois, Estados Unidos, 60504
        • Rush-Copley Medical Center
      • Bloomington, Illinois, Estados Unidos, 61704
        • Illinois CancerCare-Bloomington
      • Canton, Illinois, Estados Unidos, 61520
        • Illinois CancerCare-Canton
      • Carbondale, Illinois, Estados Unidos, 62902
        • Memorial Hospital of Carbondale
      • Carterville, Illinois, Estados Unidos, 62918
        • SIH Cancer Institute
      • Carthage, Illinois, Estados Unidos, 62321
        • Illinois CancerCare-Carthage
      • Centralia, Illinois, Estados Unidos, 62801
        • Centralia Oncology Clinic
      • Chicago, Illinois, Estados Unidos, 60611
        • Northwestern University
      • Chicago, Illinois, Estados Unidos, 60612
        • University of Illinois
      • Chicago, Illinois, Estados Unidos, 60612
        • Rush MD Anderson Cancer Center
      • Danville, Illinois, Estados Unidos, 61832
        • Carle at The Riverfront
      • Decatur, Illinois, Estados Unidos, 62526
        • Decatur Memorial Hospital
      • Decatur, Illinois, Estados Unidos, 62526
        • Cancer Care Specialists of Illinois - Decatur
      • Dixon, Illinois, Estados Unidos, 61021
        • Illinois CancerCare-Dixon
      • Effingham, Illinois, Estados Unidos, 62401
        • Crossroads Cancer Center
      • Effingham, Illinois, Estados Unidos, 62401
        • Carle Physician Group-Effingham
      • Eureka, Illinois, Estados Unidos, 61530
        • Illinois CancerCare-Eureka
      • Galesburg, Illinois, Estados Unidos, 61401
        • Western Illinois Cancer Treatment Center
      • Galesburg, Illinois, Estados Unidos, 61401
        • Illinois CancerCare-Galesburg
      • Joliet, Illinois, Estados Unidos, 60435
        • Duly Health and Care Joliet
      • Kewanee, Illinois, Estados Unidos, 61443
        • Illinois CancerCare-Kewanee Clinic
      • Macomb, Illinois, Estados Unidos, 61455
        • Illinois CancerCare-Macomb
      • Mattoon, Illinois, Estados Unidos, 61938
        • Carle Physician Group-Mattoon/Charleston
      • Mount Vernon, Illinois, Estados Unidos, 62864
        • SSM Health Good Samaritan
      • O'Fallon, Illinois, Estados Unidos, 62269
        • Cancer Care Center of O'Fallon
      • Ottawa, Illinois, Estados Unidos, 61350
        • Illinois CancerCare-Ottawa Clinic
      • Pekin, Illinois, Estados Unidos, 61554
        • Illinois CancerCare-Pekin
      • Peoria, Illinois, Estados Unidos, 61636
        • Methodist Medical Center of Illinois
      • Peoria, Illinois, Estados Unidos, 61615
        • Illinois CancerCare-Peoria
      • Peru, Illinois, Estados Unidos, 61354
        • Illinois CancerCare-Peru
      • Peru, Illinois, Estados Unidos, 61354
        • Valley Radiation Oncology
      • Princeton, Illinois, Estados Unidos, 61356
        • Illinois CancerCare-Princeton
      • Springfield, Illinois, Estados Unidos, 62702
        • Southern Illinois University School of Medicine
      • Springfield, Illinois, Estados Unidos, 62702
        • Springfield Clinic
      • Springfield, Illinois, Estados Unidos, 62781
        • Springfield Memorial Hospital
      • Swansea, Illinois, Estados Unidos, 62226
        • Southwest Illinois Health Services LLP
      • Urbana, Illinois, Estados Unidos, 61801
        • Carle Cancer Center
      • Urbana, Illinois, Estados Unidos, 61801
        • The Carle Foundation Hospital
      • Washington, Illinois, Estados Unidos, 61571
        • Illinois CancerCare - Washington
      • Yorkville, Illinois, Estados Unidos, 60560
        • Rush-Copley Healthcare Center
    • Indiana
      • Evansville, Indiana, Estados Unidos, 47713
        • Deaconess Clinic Downtown
      • Indianapolis, Indiana, Estados Unidos, 46202
        • Indiana University/Melvin and Bren Simon Cancer Center
      • Newburgh, Indiana, Estados Unidos, 47630
        • Chancellor Center for Oncology
    • Iowa
      • Clive, Iowa, Estados Unidos, 50325
        • Mercy Cancer Center-West Lakes
      • Clive, Iowa, Estados Unidos, 50325
        • UI Health Care Mission Cancer and Blood - West Des Moines Clinic
      • Council Bluffs, Iowa, Estados Unidos, 51503
        • Alegent Health Mercy Hospital
      • Creston, Iowa, Estados Unidos, 50801
        • Greater Regional Medical Center
      • Des Moines, Iowa, Estados Unidos, 50314
        • Mercy Medical Center - Des Moines
      • Des Moines, Iowa, Estados Unidos, 50314
        • UI Health Care Mission Cancer and Blood - Laurel Clinic
      • West Des Moines, Iowa, Estados Unidos, 50266
        • Mercy Medical Center-West Lakes
    • Kansas
      • Garden City, Kansas, Estados Unidos, 67846
        • Central Care Cancer Center - Garden City
      • Great Bend, Kansas, Estados Unidos, 67530
        • Central Care Cancer Center - Great Bend
    • Kentucky
      • Bardstown, Kentucky, Estados Unidos, 40004
        • CommonSpirit Saint Joseph Hospital - Bardstown
      • Corbin, Kentucky, Estados Unidos, 40701
        • Commonwealth Cancer Center-Corbin
      • Lexington, Kentucky, Estados Unidos, 40504
        • Saint Joseph Radiation Oncology Resource Center
      • Lexington, Kentucky, Estados Unidos, 40509
        • CommonSpirit Saint Joseph Medical Center - East Lexington
      • London, Kentucky, Estados Unidos, 40741
        • CommonSpirit Saint Joseph Hospital London
      • Louisville, Kentucky, Estados Unidos, 40202
        • Jewish Hospital
      • Louisville, Kentucky, Estados Unidos, 40245
        • UofL Health Medical Center Northeast
      • Louisville, Kentucky, Estados Unidos, 40215
        • Saints Mary and Elizabeth Hospital
      • Paducah, Kentucky, Estados Unidos, 42003
        • Mercy Health - Paducah Cancer Center
      • Shepherdsville, Kentucky, Estados Unidos, 40165
        • Jewish Hospital Medical Center South
    • Louisiana
      • Baton Rouge, Louisiana, Estados Unidos, 70805
        • LSU Health Baton Rouge-North Clinic
      • Baton Rouge, Louisiana, Estados Unidos, 70809
        • Louisiana Hematology Oncology Associates LLC
      • Baton Rouge, Louisiana, Estados Unidos, 70809
        • Mary Bird Perkins Cancer Center
      • Baton Rouge, Louisiana, Estados Unidos, 70808
        • Our Lady of The Lake
      • Baton Rouge, Louisiana, Estados Unidos, 70808
        • Our Lady of the Lake Physician Group
      • Covington, Louisiana, Estados Unidos, 70433
        • Northshore Oncology Associates-Covington
      • Houma, Louisiana, Estados Unidos, 70360
        • Terrebonne General Medical Center
      • Houma, Louisiana, Estados Unidos, 70360
        • Oncology Center of The South Incorporated
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21287
        • Johns Hopkins University/Sidney Kimmel Cancer Center
      • Baltimore, Maryland, Estados Unidos, 21229
        • Saint Agnes Hospital
      • Bethesda, Maryland, Estados Unidos, 20889-5600
        • Walter Reed National Military Medical Center
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02111
        • Tufts Medical Center
    • Michigan
      • Port Huron, Michigan, Estados Unidos, 48060
        • Lake Huron Medical Center
      • Port Huron, Michigan, Estados Unidos, 48060
        • Huron Medical Center PC
    • Minnesota
      • Aitkin, Minnesota, Estados Unidos, 56431
        • Riverwood Healthcare Center
      • Brainerd, Minnesota, Estados Unidos, 56401
        • Essentia Health Saint Joseph's Medical Center
      • Deer River, Minnesota, Estados Unidos, 56636
        • Essentia Health - Deer River Clinic
      • Detroit Lakes, Minnesota, Estados Unidos, 56501
        • Essentia Health Saint Mary's - Detroit Lakes Clinic
      • Duluth, Minnesota, Estados Unidos, 55805
        • Essentia Health Cancer Center
      • Duluth, Minnesota, Estados Unidos, 55805
        • Essentia Health Saint Mary's Medical Center
      • Duluth, Minnesota, Estados Unidos, 55805
        • Miller-Dwan Hospital
      • Fergus Falls, Minnesota, Estados Unidos, 56537
        • Lake Region Healthcare Corporation-Cancer Care
      • Fosston, Minnesota, Estados Unidos, 56542
        • Essentia Health - Fosston
      • Hibbing, Minnesota, Estados Unidos, 55746
        • Essentia Health Hibbing Clinic
      • Park Rapids, Minnesota, Estados Unidos, 56470
        • Essentia Health - Park Rapids
      • Rochester, Minnesota, Estados Unidos, 55905
        • Mayo Clinic in Rochester
      • Sandstone, Minnesota, Estados Unidos, 55072
        • Essentia Health Sandstone
      • Virginia, Minnesota, Estados Unidos, 55792
        • Essentia Health Virginia Clinic
    • Missouri
      • Ballwin, Missouri, Estados Unidos, 63011
        • Mercy Oncology and Hematology - Clayton-Clarkson
      • Bolivar, Missouri, Estados Unidos, 65613
        • Central Care Cancer Center - Bolivar
      • Bonne Terre, Missouri, Estados Unidos, 63628
        • Parkland Health Center-Bonne Terre
      • Branson, Missouri, Estados Unidos, 65616
        • Cox Cancer Center Branson
      • Cape Girardeau, Missouri, Estados Unidos, 63703
        • Saint Francis Medical Center
      • Cape Girardeau, Missouri, Estados Unidos, 63703
        • Mercy Cancer Center - Cape Girardeau
      • Chesterfield, Missouri, Estados Unidos, 63017
        • Saint Luke's Hospital
      • City of Saint Peters, Missouri, Estados Unidos, 63376
        • Siteman Cancer Center at Saint Peters Hospital
      • Creve Coeur, Missouri, Estados Unidos, 63141
        • Siteman Cancer Center at West County Hospital
      • Farmington, Missouri, Estados Unidos, 63640
        • Parkland Health Center - Farmington
      • Jefferson City, Missouri, Estados Unidos, 65109
        • MU Health Care Goldschmidt Cancer Center
      • Joplin, Missouri, Estados Unidos, 64804
        • Freeman Health System
      • Joplin, Missouri, Estados Unidos, 64804
        • Mercy Hospital Joplin
      • Kansas City, Missouri, Estados Unidos, 64108
        • Children's Mercy Hospitals and Clinics
      • Rolla, Missouri, Estados Unidos, 65401
        • Mercy Clinic-Rolla-Cancer and Hematology
      • Rolla, Missouri, Estados Unidos, 65401
        • Phelps Health Delbert Day Cancer Institute
      • Saint Joseph, Missouri, Estados Unidos, 64506
        • Heartland Regional Medical Center
      • Sainte Genevieve, Missouri, Estados Unidos, 63670
        • Sainte Genevieve County Memorial Hospital
      • Springfield, Missouri, Estados Unidos, 65807
        • CoxHealth South Hospital
      • Springfield, Missouri, Estados Unidos, 65804
        • Mercy Hospital Springfield
      • St Louis, Missouri, Estados Unidos, 63110
        • Washington University School of Medicine
      • St Louis, Missouri, Estados Unidos, 63129
        • Siteman Cancer Center-South County
      • St Louis, Missouri, Estados Unidos, 63136
        • Siteman Cancer Center at Christian Hospital
      • St Louis, Missouri, Estados Unidos, 63131
        • Missouri Baptist Medical Center
      • St Louis, Missouri, Estados Unidos, 63109
        • Mercy Infusion Center - Chippewa
      • St Louis, Missouri, Estados Unidos, 63141
        • Mercy Hospital Saint Louis
      • St Louis, Missouri, Estados Unidos, 63128
        • Mercy Hospital South
      • Sullivan, Missouri, Estados Unidos, 63080
        • Missouri Baptist Sullivan Hospital
      • Washington, Missouri, Estados Unidos, 63090
        • Mercy Hospital Washington
    • Montana
      • Anaconda, Montana, Estados Unidos, 59711
        • Community Hospital of Anaconda
      • Billings, Montana, Estados Unidos, 59101
        • Billings Clinic Cancer Center
      • Billings, Montana, Estados Unidos, 59101
        • Saint Vincent Healthcare
      • Billings, Montana, Estados Unidos, 59102
        • Saint Vincent Frontier Cancer Center
      • Bozeman, Montana, Estados Unidos, 59715
        • Bozeman Health Deaconess Hospital
      • Butte, Montana, Estados Unidos, 59701
        • Saint James Community Hospital and Cancer Treatment Center
      • Great Falls, Montana, Estados Unidos, 59405
        • Great Falls Clinic
      • Great Falls, Montana, Estados Unidos, 59405
        • Benefis Sletten Cancer Institute
      • Helena, Montana, Estados Unidos, 59601
        • Saint Peter's Community Hospital
      • Kalispell, Montana, Estados Unidos, 59901
        • Logan Health Medical Center
      • Missoula, Montana, Estados Unidos, 59802
        • Saint Patrick Hospital - Community Hospital
      • Missoula, Montana, Estados Unidos, 59804
        • Community Medical Center
    • Nebraska
      • Grand Island, Nebraska, Estados Unidos, 68803
        • Nebraska Cancer Specialists/Oncology Hematology West PC
      • Kearney, Nebraska, Estados Unidos, 68847
        • CHI Health Good Samaritan
      • Kearney, Nebraska, Estados Unidos, 68845
        • Fred and Pamela Buffett Cancer Center - Kearney
      • Lincoln, Nebraska, Estados Unidos, 68510
        • Saint Elizabeth Regional Medical Center
      • Omaha, Nebraska, Estados Unidos, 68124
        • Alegent Health Bergan Mercy Medical Center
      • Omaha, Nebraska, Estados Unidos, 68122
        • Alegent Health Immanuel Medical Center
      • Omaha, Nebraska, Estados Unidos, 68130
        • Alegent Health Lakeside Hospital
      • Omaha, Nebraska, Estados Unidos, 68122
        • Hematology and Oncology Consultants PC
      • Papillion, Nebraska, Estados Unidos, 68046
        • Midlands Community Hospital
    • Nevada
      • Carson City, Nevada, Estados Unidos, 89703
        • Carson Tahoe Regional Medical Center
      • Henderson, Nevada, Estados Unidos, 89052
        • Comprehensive Cancer Centers of Nevada - Henderson
      • Henderson, Nevada, Estados Unidos, 89052
        • Cancer and Blood Specialists-Henderson
      • Henderson, Nevada, Estados Unidos, 89052
        • Las Vegas Cancer Center-Henderson
      • Henderson, Nevada, Estados Unidos, 89074
        • Comprehensive Cancer Centers of Nevada-Southeast Henderson
      • Henderson, Nevada, Estados Unidos, 89052
        • Comprehensive Cancer Centers of Nevada-Horizon Ridge
      • Henderson, Nevada, Estados Unidos, 89074
        • Las Vegas Urology - Green Valley
      • Henderson, Nevada, Estados Unidos, 89074
        • Las Vegas Urology - Pebble
      • Henderson, Nevada, Estados Unidos, 89074
        • Urology Specialists of Nevada - Green Valley
      • Henderson, Nevada, Estados Unidos, 89074
        • Oncology Las Vegas - Henderson
      • Las Vegas, Nevada, Estados Unidos, 89144
        • Summerlin Hospital Medical Center
      • Las Vegas, Nevada, Estados Unidos, 89109
        • Sunrise Hospital and Medical Center
      • Las Vegas, Nevada, Estados Unidos, 89102
        • OptumCare Cancer Care at Charleston
      • Las Vegas, Nevada, Estados Unidos, 89106
        • Radiation Oncology Centers of Nevada Central
      • Las Vegas, Nevada, Estados Unidos, 89119
        • Radiation Oncology Centers of Nevada Southeast
      • Las Vegas, Nevada, Estados Unidos, 89128
        • Comprehensive Cancer Centers of Nevada - Northwest
      • Las Vegas, Nevada, Estados Unidos, 89128
        • OptumCare Cancer Care at MountainView
      • Las Vegas, Nevada, Estados Unidos, 89135
        • Alliance for Childhood Diseases/Cure 4 the Kids Foundation
      • Las Vegas, Nevada, Estados Unidos, 89144
        • Comprehensive Cancer Centers of Nevada - Town Center
      • Las Vegas, Nevada, Estados Unidos, 89144
        • Comprehensive Cancer Centers of Nevada-Summerlin
      • Las Vegas, Nevada, Estados Unidos, 89148
        • Comprehensive Cancer Centers of Nevada
      • Las Vegas, Nevada, Estados Unidos, 89169
        • Comprehensive Cancer Centers of Nevada - Central Valley
      • Las Vegas, Nevada, Estados Unidos, 89102
        • University Medical Center of Southern Nevada
      • Las Vegas, Nevada, Estados Unidos, 89106
        • Cancer and Blood Specialists-Shadow
      • Las Vegas, Nevada, Estados Unidos, 89109
        • HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway
      • Las Vegas, Nevada, Estados Unidos, 89113
        • HealthCare Partners Medical Group Oncology/Hematology-San Martin
      • Las Vegas, Nevada, Estados Unidos, 89128
        • Cancer and Blood Specialists-Tenaya
      • Las Vegas, Nevada, Estados Unidos, 89128
        • HealthCare Partners Medical Group Oncology/Hematology-Tenaya
      • Las Vegas, Nevada, Estados Unidos, 89148-2405
        • Las Vegas Cancer Center-Medical Center
      • Las Vegas, Nevada, Estados Unidos, 89149
        • HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills
      • Las Vegas, Nevada, Estados Unidos, 89128
        • Ann M Wierman MD LTD
      • Las Vegas, Nevada, Estados Unidos, 89074
        • Las Vegas Urology - Pecos
      • Las Vegas, Nevada, Estados Unidos, 89102
        • Desert West Surgery
      • Las Vegas, Nevada, Estados Unidos, 89103
        • Hope Cancer Care of Nevada
      • Las Vegas, Nevada, Estados Unidos, 89106
        • Urology Specialists of Nevada - Central
      • Las Vegas, Nevada, Estados Unidos, 89113
        • Las Vegas Prostate Cancer Center
      • Las Vegas, Nevada, Estados Unidos, 89113
        • Las Vegas Urology - Sunset
      • Las Vegas, Nevada, Estados Unidos, 89128
        • Las Vegas Urology - Cathedral Rock
      • Las Vegas, Nevada, Estados Unidos, 89128
        • Las Vegas Urology - Smoke Ranch
      • Las Vegas, Nevada, Estados Unidos, 89128
        • Urology Specialists of Nevada - Northwest
      • Las Vegas, Nevada, Estados Unidos, 89169
        • University Cancer Center
      • Las Vegas, Nevada, Estados Unidos, 89113
        • Urology Specialists of Nevada - Southwest
      • Las Vegas, Nevada, Estados Unidos, 89128
        • Oncology Las Vegas - Tenaya
      • Las Vegas, Nevada, Estados Unidos, 89183
        • OptumCare Cancer Care at Fort Apache
      • Pahrump, Nevada, Estados Unidos, 89048
        • Hope Cancer Care of Nevada-Pahrump
      • Reno, Nevada, Estados Unidos, 89502
        • Renown Regional Medical Center
      • Reno, Nevada, Estados Unidos, 89503
        • Saint Mary's Regional Medical Center
      • Reno, Nevada, Estados Unidos, 89509
        • Radiation Oncology Associates
    • New Jersey
      • Hackensack, New Jersey, Estados Unidos, 07601
        • Hackensack University Medical Center
      • Lakewood, New Jersey, Estados Unidos, 08701
        • Monmouth Medical Center Southern Campus
      • Long Branch, New Jersey, Estados Unidos, 07740
        • Monmouth Medical Center
      • Morristown, New Jersey, Estados Unidos, 07960
        • Morristown Medical Center
      • New Brunswick, New Jersey, Estados Unidos, 08903
        • Rutgers Cancer Institute of New Jersey
      • New Brunswick, New Jersey, Estados Unidos, 08903
        • Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
    • New Mexico
      • Albuquerque, New Mexico, Estados Unidos, 87106
        • University of New Mexico Cancer Center
    • New York
      • Albany, New York, Estados Unidos, 12208
        • Albany Medical Center
      • Buffalo, New York, Estados Unidos, 14263
        • Roswell Park Cancer Institute
      • New York, New York, Estados Unidos, 10065
        • Memorial Sloan Kettering Cancer Center
      • New York, New York, Estados Unidos, 10029
        • Mount Sinai Hospital
      • New York, New York, Estados Unidos, 10032
        • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
      • New York, New York, Estados Unidos, 10065
        • NYP/Weill Cornell Medical Center
      • New York, New York, Estados Unidos, 10016
        • Laura and Isaac Perlmutter Cancer Center at NYU Langone
      • Stony Brook, New York, Estados Unidos, 11794
        • Stony Brook University Medical Center
      • Syracuse, New York, Estados Unidos, 13210
        • State University of New York Upstate Medical University
      • The Bronx, New York, Estados Unidos, 10467
        • Montefiore Medical Center - Moses Campus
    • North Carolina
      • Chapel Hill, North Carolina, Estados Unidos, 27599
        • UNC Lineberger Comprehensive Cancer Center
      • Charlotte, North Carolina, Estados Unidos, 28203
        • Carolinas Medical Center/Levine Cancer Institute
      • Clinton, North Carolina, Estados Unidos, 28328
        • Southeastern Medical Oncology Center-Clinton
      • Goldsboro, North Carolina, Estados Unidos, 27534
        • Southeastern Medical Oncology Center-Goldsboro
      • Goldsboro, North Carolina, Estados Unidos, 27534
        • Wayne Memorial Hospital
      • Jacksonville, North Carolina, Estados Unidos, 28546
        • Southeastern Medical Oncology Center-Jacksonville
      • Jacksonville, North Carolina, Estados Unidos, 28546
        • Onslow Memorial Hospital
    • North Dakota
      • Fargo, North Dakota, Estados Unidos, 58103
        • Essentia Health Cancer Center-South University Clinic
      • Jamestown, North Dakota, Estados Unidos, 58401
        • Essentia Health - Jamestown Clinic
    • Ohio
      • Akron, Ohio, Estados Unidos, 44308
        • Children's Hospital Medical Center of Akron
      • Cincinnati, Ohio, Estados Unidos, 45229
        • Cincinnati Children's Hospital Medical Center
      • Cincinnati, Ohio, Estados Unidos, 45220
        • Good Samaritan Hospital - Cincinnati
      • Cincinnati, Ohio, Estados Unidos, 45242
        • Bethesda North Hospital
      • Cincinnati, Ohio, Estados Unidos, 45247
        • TriHealth Cancer Institute-Westside
      • Cincinnati, Ohio, Estados Unidos, 45255
        • TriHealth Cancer Institute-Anderson
      • Cleveland, Ohio, Estados Unidos, 44109
        • MetroHealth Medical Center
      • Columbus, Ohio, Estados Unidos, 43205
        • Nationwide Children's Hospital
    • Oklahoma
      • Lawton, Oklahoma, Estados Unidos, 73505
        • Cancer Centers of Southwest Oklahoma Research
      • Oklahoma City, Oklahoma, Estados Unidos, 73104
        • University of Oklahoma Health Sciences Center
      • Oklahoma City, Oklahoma, Estados Unidos, 73120
        • Mercy Hospital Oklahoma City
      • Tulsa, Oklahoma, Estados Unidos, 74146
        • Oklahoma Cancer Specialists and Research Institute-Tulsa
    • Oregon
      • Baker City, Oregon, Estados Unidos, 97814
        • Saint Alphonsus Cancer Care Center-Baker City
      • Bend, Oregon, Estados Unidos, 97701
        • Saint Charles Health System
      • Clackamas, Oregon, Estados Unidos, 97015
        • Clackamas Radiation Oncology Center
      • Clackamas, Oregon, Estados Unidos, 97015
        • Providence Cancer Institute Clackamas Clinic
      • Coos Bay, Oregon, Estados Unidos, 97420
        • Bay Area Hospital
      • Newberg, Oregon, Estados Unidos, 97132
        • Providence Newberg Medical Center
      • Ontario, Oregon, Estados Unidos, 97914
        • Saint Alphonsus Cancer Care Center-Ontario
      • Oregon City, Oregon, Estados Unidos, 97045
        • Providence Willamette Falls Medical Center
      • Portland, Oregon, Estados Unidos, 97213
        • Providence Portland Medical Center
      • Portland, Oregon, Estados Unidos, 97225
        • Providence Saint Vincent Medical Center
      • Redmond, Oregon, Estados Unidos, 97756
        • Saint Charles Health System-Redmond
    • Pennsylvania
      • Hershey, Pennsylvania, Estados Unidos, 17033-0850
        • Penn State Milton S Hershey Medical Center
      • Philadelphia, Pennsylvania, Estados Unidos, 19111
        • Fox Chase Cancer Center
      • Philadelphia, Pennsylvania, Estados Unidos, 19104
        • Children's Hospital of Philadelphia
      • Philadelphia, Pennsylvania, Estados Unidos, 19104
        • University of Pennsylvania/Abramson Cancer Center
    • South Carolina
      • Boiling Springs, South Carolina, Estados Unidos, 29316
        • Prisma Health Cancer Institute - Spartanburg
      • Columbia, South Carolina, Estados Unidos, 29203
        • Prisma Health Richland Hospital
      • Easley, South Carolina, Estados Unidos, 29640
        • Prisma Health Cancer Institute - Easley
      • Greenville, South Carolina, Estados Unidos, 29605
        • Prisma Health Cancer Institute - Faris
      • Greenville, South Carolina, Estados Unidos, 29607
        • Saint Francis Cancer Center
      • Greenville, South Carolina, Estados Unidos, 29615
        • Prisma Health Cancer Institute - Eastside
      • Greenville, South Carolina, Estados Unidos, 29605
        • Prisma Health Cancer Institute - Butternut
      • Greenville, South Carolina, Estados Unidos, 29601
        • Saint Francis Hospital
      • Greenville, South Carolina, Estados Unidos, 29605
        • BI-LO Charities Children's Cancer Center
      • Greenville, South Carolina, Estados Unidos, 29605
        • Prisma Health Greenville Memorial Hospital
      • Greer, South Carolina, Estados Unidos, 29650
        • Prisma Health Cancer Institute - Greer
      • Seneca, South Carolina, Estados Unidos, 29672
        • Prisma Health Cancer Institute - Seneca
    • Tennessee
      • Chattanooga, Tennessee, Estados Unidos, 37404
        • Memorial Hospital
      • Hixson, Tennessee, Estados Unidos, 37343
        • Pulmonary Medicine Center of Chattanooga-Hixson
      • Knoxville, Tennessee, Estados Unidos, 37916
        • East Tennessee Childrens Hospital
      • Memphis, Tennessee, Estados Unidos, 38105
        • Saint Jude Children's Research Hospital
      • Nashville, Tennessee, Estados Unidos, 37232
        • Vanderbilt University/Ingram Cancer Center
      • Nashville, Tennessee, Estados Unidos, 37203
        • The Children's Hospital at TriStar Centennial
      • Ooltewah, Tennessee, Estados Unidos, 37363
        • Memorial GYN Plus
    • Texas
      • Austin, Texas, Estados Unidos, 78723
        • Dell Children's Medical Center of Central Texas
      • Bryan, Texas, Estados Unidos, 77802
        • Saint Joseph Regional Cancer Center
      • Corpus Christi, Texas, Estados Unidos, 78411
        • Driscoll Children's Hospital
      • El Paso, Texas, Estados Unidos, 79905
        • El Paso Children's Hospital
      • Fort Worth, Texas, Estados Unidos, 76104
        • Cook Children's Medical Center
      • San Antonio, Texas, Estados Unidos, 78207
        • Children's Hospital of San Antonio
    • Utah
      • American Fork, Utah, Estados Unidos, 84003
        • American Fork Hospital / Huntsman Intermountain Cancer Center
      • Cedar City, Utah, Estados Unidos, 84720
        • Sandra L Maxwell Cancer Center
      • Logan, Utah, Estados Unidos, 84321
        • Logan Regional Hospital
      • Murray, Utah, Estados Unidos, 84107
        • Intermountain Medical Center
      • Ogden, Utah, Estados Unidos, 84403
        • McKay-Dee Hospital Center
      • Riverton, Utah, Estados Unidos, 84065
        • Riverton Hospital
      • Salt Lake City, Utah, Estados Unidos, 84106
        • Utah Cancer Specialists-Salt Lake City
      • Salt Lake City, Utah, Estados Unidos, 84143
        • LDS Hospital
      • St. George, Utah, Estados Unidos, 84770
        • Saint George Regional Medical Center
    • Virginia
      • Norfolk, Virginia, Estados Unidos, 23507
        • Children's Hospital of The King's Daughters
    • Washington
      • Aberdeen, Washington, Estados Unidos, 98520
        • Providence Regional Cancer System-Aberdeen
      • Auburn, Washington, Estados Unidos, 98001
        • MultiCare Auburn Medical Center
      • Bellevue, Washington, Estados Unidos, 98004
        • Overlake Medical Center
      • Bellingham, Washington, Estados Unidos, 98225
        • PeaceHealth Saint Joseph Medical Center
      • Burien, Washington, Estados Unidos, 98166
        • Saint Anne Hospital
      • Centralia, Washington, Estados Unidos, 98531
        • Providence Regional Cancer System-Centralia
      • Edmonds, Washington, Estados Unidos, 98026
        • Swedish Cancer Institute-Edmonds
      • Enumclaw, Washington, Estados Unidos, 98022
        • Saint Elizabeth Hospital
      • Everett, Washington, Estados Unidos, 98201
        • Providence Regional Cancer Partnership
      • Federal Way, Washington, Estados Unidos, 98003
        • Saint Francis Hospital
      • Gig Harbor, Washington, Estados Unidos, 98335
        • MultiCare Gig Harbor Medical Park
      • Issaquah, Washington, Estados Unidos, 98029
        • Swedish Cancer Institute-Issaquah
      • Kennewick, Washington, Estados Unidos, 99336
        • Kadlec Clinic Hematology and Oncology
      • Lacey, Washington, Estados Unidos, 98503
        • Providence Regional Cancer System-Lacey
      • Lakewood, Washington, Estados Unidos, 98499
        • Saint Clare Hospital
      • Longview, Washington, Estados Unidos, 98632
        • PeaceHealth Saint John Medical Center
      • Port Townsend, Washington, Estados Unidos, 98368
        • Jefferson Healthcare
      • Poulsbo, Washington, Estados Unidos, 98370
        • Harrison HealthPartners Hematology and Oncology-Poulsbo
      • Puyallup, Washington, Estados Unidos, 98372
        • MultiCare Good Samaritan Hospital
      • Renton, Washington, Estados Unidos, 98055
        • Valley Medical Center
      • Seattle, Washington, Estados Unidos, 98105
        • Seattle Children's Hospital
      • Seattle, Washington, Estados Unidos, 98107
        • Swedish Medical Center-Ballard Campus
      • Seattle, Washington, Estados Unidos, 98122
        • Swedish Medical Center-First Hill
      • Seattle, Washington, Estados Unidos, 98112
        • Kaiser Permanente Washington
      • Seattle, Washington, Estados Unidos, 98104
        • Pacific Gynecology Specialists
      • Seattle, Washington, Estados Unidos, 98122-5711
        • Swedish Medical Center-Cherry Hill
      • Sedro-Woolley, Washington, Estados Unidos, 98284
        • PeaceHealth United General Medical Center
      • Shelton, Washington, Estados Unidos, 98584
        • Providence Regional Cancer System-Shelton
      • Silverdale, Washington, Estados Unidos, 98383
        • Saint Joseph Medical Center Hematology and Oncology - Silverdale
      • Spokane, Washington, Estados Unidos, 99204
        • Providence Sacred Heart Medical Center and Children's Hospital
      • Spokane, Washington, Estados Unidos, 99204
        • MultiCare Deaconess Cancer and Blood Specialty Center - Downtown
      • Spokane, Washington, Estados Unidos, 99218
        • MultiCare Deaconess Cancer and Blood Specialty Center - North
      • Spokane Valley, Washington, Estados Unidos, 99216
        • MultiCare Deaconess Cancer and Blood Specialty Center - Valley
      • Tacoma, Washington, Estados Unidos, 98405
        • Mary Bridge Children's Hospital and Health Center
      • Tacoma, Washington, Estados Unidos, 98405
        • Northwest Medical Specialties PLLC
      • Tacoma, Washington, Estados Unidos, 98431
        • Madigan Army Medical Center
      • Tacoma, Washington, Estados Unidos, 98405
        • MultiCare Tacoma General Hospital
      • Tacoma, Washington, Estados Unidos, 98405
        • Franciscan Research Center-Northwest Medical Plaza
      • Vancouver, Washington, Estados Unidos, 98664
        • PeaceHealth Southwest Medical Center
      • Walla Walla, Washington, Estados Unidos, 99362
        • Providence Saint Mary Regional Cancer Center
      • Yakima, Washington, Estados Unidos, 98902
        • North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
      • Yelm, Washington, Estados Unidos, 98597
        • Providence Regional Cancer System-Yelm
    • West Virginia
      • Bridgeport, West Virginia, Estados Unidos, 26330
        • United Hospital Center
      • Martinsburg, West Virginia, Estados Unidos, 25401
        • WVUH-Berkely Medical Center
      • Morgantown, West Virginia, Estados Unidos, 26506
        • West Virginia University Healthcare
      • Parkersburg, West Virginia, Estados Unidos, 26101
        • Camden Clark Medical Center
    • Wisconsin
      • Ashland, Wisconsin, Estados Unidos, 54806
        • Duluth Clinic Ashland
      • Ashland, Wisconsin, Estados Unidos, 54806
        • Northwest Wisconsin Cancer Center
      • Burlington, Wisconsin, Estados Unidos, 53105
        • Aurora Cancer Care-Southern Lakes VLCC
      • Chippewa Falls, Wisconsin, Estados Unidos, 54729
        • Marshfield Clinic-Chippewa Center
      • Eau Claire, Wisconsin, Estados Unidos, 54701
        • Marshfield Medical Center-EC Cancer Center
      • Fond du Lac, Wisconsin, Estados Unidos, 54937
        • Aurora Health Center-Fond du Lac
      • Germantown, Wisconsin, Estados Unidos, 53022
        • Aurora Health Care Germantown Health Center
      • Grafton, Wisconsin, Estados Unidos, 53024
        • Aurora Cancer Care-Grafton
      • Green Bay, Wisconsin, Estados Unidos, 54311
        • Aurora BayCare Medical Center
      • Kenosha, Wisconsin, Estados Unidos, 53142
        • Aurora Cancer Care-Kenosha South
      • La Crosse, Wisconsin, Estados Unidos, 54601
        • Gundersen Lutheran Medical Center
      • Ladysmith, Wisconsin, Estados Unidos, 54848
        • Marshfield Medical Center - Ladysmith
      • Madison, Wisconsin, Estados Unidos, 53792
        • University of Wisconsin Carbone Cancer Center - University Hospital
      • Marinette, Wisconsin, Estados Unidos, 54143
        • Aurora Bay Area Medical Group-Marinette
      • Marshfield, Wisconsin, Estados Unidos, 54449
        • Marshfield Medical Center-Marshfield
      • Milwaukee, Wisconsin, Estados Unidos, 53226
        • Medical College of Wisconsin
      • Milwaukee, Wisconsin, Estados Unidos, 53209
        • Aurora Cancer Care-Milwaukee
      • Milwaukee, Wisconsin, Estados Unidos, 53215
        • Aurora Saint Luke's Medical Center
      • Milwaukee, Wisconsin, Estados Unidos, 53233
        • Aurora Sinai Medical Center
      • Minocqua, Wisconsin, Estados Unidos, 54548
        • Marshfield Medical Center - Minocqua
      • Oshkosh, Wisconsin, Estados Unidos, 54904
        • Vince Lombardi Cancer Clinic - Oshkosh
      • Racine, Wisconsin, Estados Unidos, 53406
        • Aurora Cancer Care-Racine
      • Rice Lake, Wisconsin, Estados Unidos, 54868
        • Marshfield Medical Center-Rice Lake
      • Sheboygan, Wisconsin, Estados Unidos, 53081
        • Vince Lombardi Cancer Clinic-Sheboygan
      • Stevens Point, Wisconsin, Estados Unidos, 54482
        • Marshfield Medical Center-River Region at Stevens Point
      • Summit, Wisconsin, Estados Unidos, 53066
        • Aurora Medical Center in Summit
      • Two Rivers, Wisconsin, Estados Unidos, 54241
        • Vince Lombardi Cancer Clinic-Two Rivers
      • Wausau, Wisconsin, Estados Unidos, 54401
        • Marshfield Clinic-Wausau Center
      • Wauwatosa, Wisconsin, Estados Unidos, 53226
        • Aurora Cancer Care-Milwaukee West
      • West Allis, Wisconsin, Estados Unidos, 53227
        • Aurora West Allis Medical Center
      • Weston, Wisconsin, Estados Unidos, 54476
        • Marshfield Medical Center - Weston
      • Wisconsin Rapids, Wisconsin, Estados Unidos, 54494
        • Marshfield Clinic - Wisconsin Rapids Center
    • Wyoming
      • Cheyenne, Wyoming, Estados Unidos, 82001
        • Cheyenne Regional Medical Center-West
      • Cody, Wyoming, Estados Unidos, 82414
        • Billings Clinic-Cody
      • Sheridan, Wyoming, Estados Unidos, 82801
        • Welch Cancer Center

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

12 anos e mais velhos (Filho, Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • PHASE I (ARMS A, B, C, D, E, F, G, H, I, X, Y, Z)

  • Age >= 18 years

  • Patients must have pathologically confirmed relapsed or refractory classical Hodgkin lymphoma (cHL); a biopsy at any relapse is acceptable; other histologies including lymphocyte predominant (LP) HL are not permitted

  • Patients must have relapsed after first line chemotherapy; may have relapsed after autologous or allogeneic stem cell transplant, or have primary refractory disease; no upper limit for number of prior therapies; if status post allogeneic stem cell transplant, no active graft versus host disease

  • Patients may have received prior brentuximab vedotin, but must not have received brentuximab vedotin within 6 months prior to registration, and must not have relapsed within 6 months of receiving previous brentuximab vedotin; patients may not have received prior nivolumab or PD1/PDL1 axis agents; patients in the nivolumab/brentuximab cohorts ONLY (D, E, F, Y) may have received prior ipilimumab

  • Patients may have received other prior activating immunotherapies (i.e. checkpoint inhibitors), but must not have received them within 6 months prior to registration, and there must be no serious unresolved complication of therapy at the time of registration; for the purposes of this study monoclonal antibodies and antibody drug conjugates are not considered to be activating immunotherapies and there are no additional time restrictions on prior exposure to these agents (except prior brentuximab vedotin)

  • Eastern Cooperative Oncology Group (ECOG)-American College of Radiology Imaging Network (ACRIN) performance status between 0-2

  • Patients must have measurable disease; baseline measurements and evaluations must be obtained within 4 weeks of registration to the study; abnormal PET scans will not constitute evaluable disease unless verified by a diagnostic quality CT scan; patients must use the same imaging modality (CT or PET/CT) throughout the study

  • Patient must not be pregnant or breast-feeding due to risk of fetal harm by the chemotherapeutic agents prescribed in this protocol; all patients of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy; a patient of childbearing potential is anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)

  • Patient of childbearing potential and/or sexually active patients must either abstain from sexual intercourse for the duration of their participation in the study or agree to use both single barrier contraception and birth control pills or implants for at least one week prior to the start of the study drug and continuing for 5 months after the last dose of study drug (for patients of childbearing potential) and for 7 months after the last dose of study drug (for patients who are sexually active with anyone of childbearing potential); should a patient become pregnant or suspect pregnancy while the patient or their partner is participating in this study, the patient (or the participating partner) should inform the treating physician immediately

  • Patients must have no evidence of dyspnea at rest and a pulse oximetry > 92% while breathing room air

  • Patients must have forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) > 60% by pulmonary function test (PFT), unless due to large mediastinal mass from HL; carbon monoxide diffusion capacity (DLCO), FEV1, and FVC all > 50% predicted value; all pulmonary function tests must be obtained within one month prior to registration

  • Absolute neutrophil count (ANC) >= 1500/mcL (1.5 x 10^9/L) (obtained within 2 weeks prior to registration)

  • Platelets >= 75,000/mcL (75 x 10^9/L) (obtained within 2 weeks prior to registration)

  • Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) (obtained within 2 weeks prior to registration)

  • Bilirubin =< 2 x upper limit of normal (ULN) (unless documented Gilbert's syndrome, for which bilirubin =< 3 x upper limit of normal [ULN] is permitted) (obtained within 2 weeks prior to registration)

  • Calculated creatinine clearance by Cockcroft-Gault formula >= 30 ml/min (obtained within 2 weeks prior to registration)

  • No evidence of prior malignancy except adequately treated non-melanoma skin cancer, in situ cervical carcinoma or any surgically- or radiation-cured malignancy continuously disease free for >= 5 years so as not to interfere with interpretation of radiographic response

  • Patient must have no current or prior history of central nervous system (CNS) involvement

  • All prior therapy must have been completed at least 21 days prior to enrollment; no concomitant anti lymphoma therapy, including systemic corticosteroids for the purpose of treatment of lymphoma are allowed; topical steroids are allowed

  • No history of Steven's Johnson's syndrome, toxic epidermal necrolysis (TEN)s syndrome, or motor neuropathy

  • Human immunodeficiency virus (HIV) positive patients are allowed on this study if they have a CD4 count > 400, and are on a stable antiviral regimen; patients with poorly controlled HIV or other chronic active viral infections will be excluded

  • Patients must not have autoimmune disorders or conditions of immunosuppression that require current ongoing treatment with systemic corticosteroids (or other systemic immunosuppressants), including oral steroids (i.e., prednisone, dexamethasone) or continuous use of topical steroid creams or ointments or ophthalmologic steroids; a history of occasional (but not continuous) use of steroid inhalers is allowed

    • Replacement doses of steroids for patients with adrenal insufficiency are allowed; patients who discontinue use of these classes of medication for at least 2 weeks prior to initiation of study treatment are eligible if, in the judgment of the treating physician investigator, the patient is not likely to require resumption of treatment with these classes of drugs during the study
    • Exclusion from this study also includes patients with a history of symptomatic autoimmune disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, Sjogren's syndrome, autoimmune vasculitis [e.g., Wegener's Granulomatosis]); motor neuropathy considered of autoimmune origin (e.g., Guillain-Barre syndrome and Myasthenia Gravis); other CNS autoimmune disease (e.g., Multiple sclerosis); patients with autoimmune hypothyroid disease or type I diabetes on replacement treatment are eligible
  • Patients must not have grade 2 or greater peripheral sensory neuropathy

  • Patients must not have New York Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia

  • Patients must not have previously existing hypersensitivity to brentuximab vedotin or ipilimumab

  • Patients must not have a serious medical or psychiatric illness likely to interfere with study participation

  • Patients must not be participating in any other clinical trial or taking any other experimental medications within 21 days prior to registration

  • Routine vaccinations, including seasonal influenza, should be given at least 2 weeks prior to study treatment; vaccines are not prohibited on study, but must be given at least 6 weeks after cycle 1 and not within 7 days of treatment

  • Patients registering to Arms D, E, F, G, H, I, X, Y must not currently be smoking tobacco or other substances and must not have smoked within the past 6 months

  • RANDOMIZED PHASE II (ARMS K AND L): Age >= 12 years

    • Pediatric patients will include any patients < 18 years of age
  • RANDOMIZED PHASE II (ARMS K AND L): Patients must have pathologically confirmed relapsed or refractory classical Hodgkin lymphoma (cHL); a biopsy at any relapse is acceptable; other histologies including lymphocyte predominant (LP) HL are not permitted

  • RANDOMIZED PHASE II (ARMS K AND L): Patients must have relapsed after first line chemotherapy; may have relapsed after autologous stem cell transplant, or have primary refractory disease; no upper limit for number of prior therapies; patient must not have received a prior allogeneic stem cell transplant (out of risk of reactivation of pulmonary graft versus host disease [GVHD])

  • RANDOMIZED PHASE II (ARMS K AND L): Patients may have received prior brentuximab vedotin, but must not have received brentuximab vedotin within 6 months prior to registration, and must not have relapsed within 6 months of receiving previous brentuximab vedotin; patients may not have received prior nivolumab or PD1/PDL1 axis agents; patients may not have received prior ipilimumab

  • RANDOMIZED PHASE II (ARMS K AND L): Patients may not have received other prior activating immunotherapies (i.e. checkpoint inhibitor therapies); for the purposes of this study monoclonal antibodies and antibody drug conjugates are not considered to be activating immunotherapies and there are no additional time restrictions on prior exposure to these agents (except prior brentuximab vedotin)

  • RANDOMIZED PHASE II (ARMS K AND L): Adult patient (>= 18 years of age) ECOG-ACRIN performance status between 0-2

    • Pediatric patients (16-17 years of age) must have a Karnofsky performance level >= 50%
    • Pediatric patients (12-15 years of age) must have a Lansky performance level >= 50
  • RANDOMIZED PHASE II (ARMS K AND L): Patients must have measurable disease; baseline measurements and evaluations must be obtained within 4 weeks of registration to the study; abnormal PET scans will not constitute evaluable disease unless verified by a diagnostic quality CT scan; patients must use the same imaging modality (CT or PET/CT) throughout the study

  • RANDOMIZED PHASE II (ARMS K AND L): Patient must not be pregnant or breast-feeding due to risk of fetal harm by the chemotherapeutic agents prescribed in this protocol; all patients of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy; a patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)

  • RANDOMIZED PHASE II (ARMS K AND L): Patient of childbearing potential and/or sexually active patient must either abstain from sexual intercourse for the duration of their participation in the study or agree to use both double barrier contraception and birth control pills or implants for at least one week prior to the start of the study drug and continuing for 5 months after the last dose of study drug (for patients of childbearing potential) and for 7 months after the last dose of study drug (for patients who are sexually active with anyone of childbearing potential); should a patient become pregnant or suspect pregnancy while the patient or their partner is participating in this study, the patient (or the participating partner) should inform the treating physician immediately

  • RANDOMIZED PHASE II (ARMS K AND L): Patients with impaired decision-making capacity are eligible with legally authorized representative

  • RANDOMIZED PHASE II (ARMS K AND L): Patients must have no evidence of dyspnea at rest and a pulse oximetry > 92% while breathing room air

  • RANDOMIZED PHASE II (ARMS K AND L): Patients must have FEV1/FVC > 60% by pulmonary function test (PFT), unless due to large mediastinal mass from HL; carbon monoxide diffusion capacity (DLCO), FEV1, and FVC all > 50% predicted value; all pulmonary function tests must be obtained within one month prior to registration

  • RANDOMIZED PHASE II (ARMS K AND L): ANC >= 1500/mcL (1.5 x 0^9/L) (obtained within 2 weeks prior to registration)

  • RANDOMIZED PHASE II (ARMS K AND L): Platelets >= 75,000/mcL (75 x 10^9/L) (obtained within 2 weeks prior to registration)

  • RANDOMIZED PHASE II (ARMS K AND L): AST/ALT =< 2.5 x upper limit of normal (ULN) for age (obtained within 2 weeks prior to registration)

  • RANDOMIZED PHASE II (ARMS K AND L): Bilirubin =< 2 x upper limit of normal (ULN) (unless documented Gilbert's syndrome, for which bilirubin =< 3 x upper limit of normal [ULN] is permitted) (obtained within 2 weeks prior to registration)

  • RANDOMIZED PHASE II (ARMS K AND L): Adult patients (>= 18 years old) must have a calculated creatinine clearance by Cockcroft-Gault formula >= 30 ml/min (obtained within 2 weeks prior to registration)

  • RANDOMIZED PHASE II (ARMS K AND L): Pediatric patients (< 18 years old) must have a creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or serum creatinine based on age/sex as follows:

    • Age: maximum serum creatinine (mg/dL)

      • < 13 years: male (1.2), female (1.2)
      • 13 to < 16 years: male (1.5), female (1.4)
      • >= 16 years: male (1.7), female (1.4)
  • RANDOMIZED PHASE II (ARMS K AND L): No evidence of prior malignancy except adequately treated non-melanoma skin cancer, in situ cervical carcinoma or any surgically- or radiation-cured malignancy continuously disease free for >= 5 years so as not to interfere with interpretation of radiographic response

  • RANDOMIZED PHASE II (ARMS K AND L): Patient must have no current or prior history of CNS involvement

  • RANDOMIZED PHASE II (ARMS K AND L): All prior therapy must have been completed at least 21 days prior to enrollment (6 weeks for nitrosoureas or mitomycin C); no concomitant anti lymphoma therapy, including systemic corticosteroids for the purpose of treatment of lymphoma are allowed; topical steroids are allowed

  • RANDOMIZED PHASE II (ARMS K AND L): No history of Steven's Johnson's syndrome, TENs syndrome, or motor neuropathy

  • RANDOMIZED PHASE II (ARMS K AND L): HIV positive patients are eligible provided they meet the other protocol criteria including the following:

    • Long term survival expected were it not for the cHL
    • HIV viral loads undetectable by standard clinical HIV testing
    • Willing to adhere to effective combination antiretroviral therapy
  • RANDOMIZED PHASE II (ARMS K AND L): Patients must not have autoimmune disorders, prior solid organ transplant, or conditions of immunosuppression that require current ongoing treatment with systemic corticosteroids (or other systemic immunosuppressants), including oral steroids (i.e., prednisone, dexamethasone) or continuous use of topical steroid creams or ointments or ophthalmologic steroids; a history of occasional (but not continuous) use of steroid inhalers is allowed; replacement doses of steroids for patients with adrenal insufficiency are allowed; patients who discontinue use of steroid medication for at least 2 weeks prior to initiation of therapy are eligible if, in the judgment of the treating physician investigator, the patient is not likely to require resumption of treatment with these classes of drugs during the study; exclusion from this study also includes patients with a history of symptomatic autoimmune disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, Sjogren's syndrome, autoimmune vasculitis [e.g., Wegener's Granulomatosis]); motor neuropathy considered of autoimmune origin (e.g., Guillain-Barre syndrome and Myasthenia Gravis); other CNS autoimmune disease (e.g., Multiple sclerosis); patients with autoimmune hypothyroid disease or type I diabetes on replacement treatment are eligible

  • RANDOMIZED PHASE II (ARMS K AND L): Patients must not have grade 2 or greater peripheral sensory neuropathy

  • RANDOMIZED PHASE II (ARMS K AND L): Patients must not have NYHA class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia

  • RANDOMIZED PHASE II (ARMS K AND L): Patients must not have previously existing hypersensitivity to brentuximab vedotin or ipilimumab

  • RANDOMIZED PHASE II (ARMS K AND L): Patients must not have a serious medical or psychiatric illness likely to interfere with study participation

  • RANDOMIZED PHASE II (ARMS K AND L): Patients must not be participating in any other clinical trial or taking any other experimental medications within 21 days prior to registration

  • RANDOMIZED PHASE II (ARMS K AND L): Routine vaccinations, including seasonal influenza, should be given at least 2 weeks prior to study treatment; vaccines are not prohibited on study, but must be given at least 6 weeks after cycle 1 and not within 7 days of treatment

  • RANDOMIZED PHASE II (ARMS K AND L): Patients must not currently be smoking tobacco or other agents; vaping is not allowed

  • RANDOMIZED PHASE II (ARMS K AND L): Patients must not have a history of or evidence of cardiovascular risks including any of the following:

    • QT interval corrected for heart rate using the Bazett's formula QTcB >= 480 msec at baseline
    • History of acute coronary syndromes (including myocardial infarction or unstable angina), coronary angioplasty, or stenting within the past 24 weeks prior to registration
    • History prior to registration or evidence of current >= class II congestive heart failure as defined by the New York Heart Association (NYHA) functional classification system
    • Left ventricular ejection fraction (LVEF) =< lower limit of normal on cardiac echocardiogram (echo) or multigated acquisition scan (MUGA)
    • Intra-cardiac defibrillator
    • History of abnormal cardiac valve morphology (>= grade 2) documented by ECHO; (subjects with grade 1 abnormalities [i.e., mild regurgitation/stenosis] can be entered on study); subjects with moderate valvular thickening should not be entered on study
    • History or evidence of current clinically significant uncontrolled cardiac arrhythmias; clarification: subjects with atrial fibrillation controlled for > 30 days prior to dosing are eligible
    • Treatment refractory hypertension defined as a blood pressure of systolic > 140 mmHg and/or diastolic > 90 mm Hg which cannot be controlled by anti-hypertensive therapy

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Phase I Arm I (brentuximab vedotin, ipilimumab)

Patients receive brentuximab vedotin IV over 30 minutes on day 1 of cycles 1-16 and ipilimumab IV over 90 minutes on day 1 of cycles 1-4, 8, 12, and 16. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study.

Given IV

Outros nomes:
  • Anticorpo Monoclonal Antigen-4 Associado a Linfócitos T Anti-Citotóxicos
  • BMS-734016
  • Ipilimumabe Biossimilar CS1002
  • MDX-010
  • MDX-CTLA4
  • Yervoy
  • MDX010
  • BMS734016
  • BMS 734016
  • MDX 010

Undergo CT

Outros nomes:
  • TC
  • GATO
  • Tomografia
  • Tomografia Axial Computadorizada
  • Tomografia computadorizada
  • tomografia
  • Tomografia axial computadorizada (procedimento)
  • Tomografia computadorizada (TC)
  • Diagnóstico Cat Scan
  • Tipo de serviço de varredura de gato diagnóstico

Undergo biopsy

Outros nomes:
  • Bx
  • TIPO DE BIÓPSIA_TIPO
  • Biópsia

Undergo collection of blood

Outros nomes:
  • Coleta de Amostras Biológicas
  • Bioespécime coletado
  • Coleta de amostras

Given IV

Outros nomes:
  • Adcetris
  • SGN-35
  • cAC10-vcMMAE
  • ADC SGN-35
  • Anti-CD30 Anticorpo-Conjugado Droga SGN-35
  • Anticorpo Monoclonal Anti-CD30-MMAE SGN-35
  • Anticorpo Monoclonal Anti-CD30-Monometilauristatina E SGN-35
  • SGN35
  • SGN 35

Undergo PET

Outros nomes:
  • Imagem Médica, Tomografia por Emissão de Pósitrons
  • BICHO DE ESTIMAÇÃO
  • PET scan
  • Tomografia por emissão de pósitrons
  • PT
  • Tomografia por emissão de pósitrons (procedimento)
Experimental: Phase I Arm II (brentuximab vedotin, nivolumab)

Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16 and nivolumab IV over 30 minutes on day 1 of cycles 1-46. Treatment repeats every 21 days for up to 16 cycles and every 14 days beginning cycle 17 for up to 46 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study.

Undergo CT

Outros nomes:
  • TC
  • GATO
  • Tomografia
  • Tomografia Axial Computadorizada
  • Tomografia computadorizada
  • tomografia
  • Tomografia axial computadorizada (procedimento)
  • Tomografia computadorizada (TC)
  • Diagnóstico Cat Scan
  • Tipo de serviço de varredura de gato diagnóstico

Undergo biopsy

Outros nomes:
  • Bx
  • TIPO DE BIÓPSIA_TIPO
  • Biópsia

Undergo collection of blood

Outros nomes:
  • Coleta de Amostras Biológicas
  • Bioespécime coletado
  • Coleta de amostras

Given IV

Outros nomes:
  • Adcetris
  • SGN-35
  • cAC10-vcMMAE
  • ADC SGN-35
  • Anti-CD30 Anticorpo-Conjugado Droga SGN-35
  • Anticorpo Monoclonal Anti-CD30-MMAE SGN-35
  • Anticorpo Monoclonal Anti-CD30-Monometilauristatina E SGN-35
  • SGN35
  • SGN 35

Undergo PET

Outros nomes:
  • Imagem Médica, Tomografia por Emissão de Pósitrons
  • BICHO DE ESTIMAÇÃO
  • PET scan
  • Tomografia por emissão de pósitrons
  • PT
  • Tomografia por emissão de pósitrons (procedimento)

Given IV

Outros nomes:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo
  • CMAB819
  • Nivolumabe Biossimilar CMAB819
  • MDX 1106
  • MDX1106
  • BMS 936558
  • ABP 206
  • Nivolumabe Biossimilar ABP 206
  • BCD-263
  • Nivolumabe Biossimilar BCD-263
  • BMS936558
  • ONO 4538
  • ONO4538
Experimental: Phase I Arm III (brentuximab vedotin, nivolumab, ipilimumab)

Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16, nivolumab IV over 30 minutes on day 1 of cycles 1-46, and ipilimumab IV over 30 minutes on day 1 every 12 weeks for up to 9 doses. Treatment repeats every 21 days for up to 16 cycles and every 14 days beginning cycle 17 for up to 46 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study.

Given IV

Outros nomes:
  • Anticorpo Monoclonal Antigen-4 Associado a Linfócitos T Anti-Citotóxicos
  • BMS-734016
  • Ipilimumabe Biossimilar CS1002
  • MDX-010
  • MDX-CTLA4
  • Yervoy
  • MDX010
  • BMS734016
  • BMS 734016
  • MDX 010

Undergo CT

Outros nomes:
  • TC
  • GATO
  • Tomografia
  • Tomografia Axial Computadorizada
  • Tomografia computadorizada
  • tomografia
  • Tomografia axial computadorizada (procedimento)
  • Tomografia computadorizada (TC)
  • Diagnóstico Cat Scan
  • Tipo de serviço de varredura de gato diagnóstico

Undergo biopsy

Outros nomes:
  • Bx
  • TIPO DE BIÓPSIA_TIPO
  • Biópsia

Undergo collection of blood

Outros nomes:
  • Coleta de Amostras Biológicas
  • Bioespécime coletado
  • Coleta de amostras

Given IV

Outros nomes:
  • Adcetris
  • SGN-35
  • cAC10-vcMMAE
  • ADC SGN-35
  • Anti-CD30 Anticorpo-Conjugado Droga SGN-35
  • Anticorpo Monoclonal Anti-CD30-MMAE SGN-35
  • Anticorpo Monoclonal Anti-CD30-Monometilauristatina E SGN-35
  • SGN35
  • SGN 35

Undergo PET

Outros nomes:
  • Imagem Médica, Tomografia por Emissão de Pósitrons
  • BICHO DE ESTIMAÇÃO
  • PET scan
  • Tomografia por emissão de pósitrons
  • PT
  • Tomografia por emissão de pósitrons (procedimento)

Given IV

Outros nomes:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo
  • CMAB819
  • Nivolumabe Biossimilar CMAB819
  • MDX 1106
  • MDX1106
  • BMS 936558
  • ABP 206
  • Nivolumabe Biossimilar ABP 206
  • BCD-263
  • Nivolumabe Biossimilar BCD-263
  • BMS936558
  • ONO 4538
  • ONO4538
Experimental: Phase II Arm I (brentuximab vedotin, nivolumab)

Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16 and nivolumab IV over 30 minutes on day 1 of cycles 1-34. Treatment repeats every 21 days for up to 34 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study.

Undergo CT

Outros nomes:
  • TC
  • GATO
  • Tomografia
  • Tomografia Axial Computadorizada
  • Tomografia computadorizada
  • tomografia
  • Tomografia axial computadorizada (procedimento)
  • Tomografia computadorizada (TC)
  • Diagnóstico Cat Scan
  • Tipo de serviço de varredura de gato diagnóstico

Undergo biopsy

Outros nomes:
  • Bx
  • TIPO DE BIÓPSIA_TIPO
  • Biópsia

Undergo collection of blood

Outros nomes:
  • Coleta de Amostras Biológicas
  • Bioespécime coletado
  • Coleta de amostras

Given IV

Outros nomes:
  • Adcetris
  • SGN-35
  • cAC10-vcMMAE
  • ADC SGN-35
  • Anti-CD30 Anticorpo-Conjugado Droga SGN-35
  • Anticorpo Monoclonal Anti-CD30-MMAE SGN-35
  • Anticorpo Monoclonal Anti-CD30-Monometilauristatina E SGN-35
  • SGN35
  • SGN 35

Undergo PET

Outros nomes:
  • Imagem Médica, Tomografia por Emissão de Pósitrons
  • BICHO DE ESTIMAÇÃO
  • PET scan
  • Tomografia por emissão de pósitrons
  • PT
  • Tomografia por emissão de pósitrons (procedimento)

Given IV

Outros nomes:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo
  • CMAB819
  • Nivolumabe Biossimilar CMAB819
  • MDX 1106
  • MDX1106
  • BMS 936558
  • ABP 206
  • Nivolumabe Biossimilar ABP 206
  • BCD-263
  • Nivolumabe Biossimilar BCD-263
  • BMS936558
  • ONO 4538
  • ONO4538
Experimental: Phase II Arm II (brentuximab vedotin, nivolumab, ipilimumab)

Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16, nivolumab IV over 30 minutes on day 1 of cycles 1-34, and ipilimumab IV over 30 minutes on day 1 every 12 weeks for up to 9 doses. Treatment repeats every 21 days for up to 34 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study.

Given IV

Outros nomes:
  • Anticorpo Monoclonal Antigen-4 Associado a Linfócitos T Anti-Citotóxicos
  • BMS-734016
  • Ipilimumabe Biossimilar CS1002
  • MDX-010
  • MDX-CTLA4
  • Yervoy
  • MDX010
  • BMS734016
  • BMS 734016
  • MDX 010

Undergo CT

Outros nomes:
  • TC
  • GATO
  • Tomografia
  • Tomografia Axial Computadorizada
  • Tomografia computadorizada
  • tomografia
  • Tomografia axial computadorizada (procedimento)
  • Tomografia computadorizada (TC)
  • Diagnóstico Cat Scan
  • Tipo de serviço de varredura de gato diagnóstico

Undergo biopsy

Outros nomes:
  • Bx
  • TIPO DE BIÓPSIA_TIPO
  • Biópsia

Undergo collection of blood

Outros nomes:
  • Coleta de Amostras Biológicas
  • Bioespécime coletado
  • Coleta de amostras

Given IV

Outros nomes:
  • Adcetris
  • SGN-35
  • cAC10-vcMMAE
  • ADC SGN-35
  • Anti-CD30 Anticorpo-Conjugado Droga SGN-35
  • Anticorpo Monoclonal Anti-CD30-MMAE SGN-35
  • Anticorpo Monoclonal Anti-CD30-Monometilauristatina E SGN-35
  • SGN35
  • SGN 35

Undergo PET

Outros nomes:
  • Imagem Médica, Tomografia por Emissão de Pósitrons
  • BICHO DE ESTIMAÇÃO
  • PET scan
  • Tomografia por emissão de pósitrons
  • PT
  • Tomografia por emissão de pósitrons (procedimento)

Given IV

Outros nomes:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo
  • CMAB819
  • Nivolumabe Biossimilar CMAB819
  • MDX 1106
  • MDX1106
  • BMS 936558
  • ABP 206
  • Nivolumabe Biossimilar ABP 206
  • BCD-263
  • Nivolumabe Biossimilar BCD-263
  • BMS936558
  • ONO 4538
  • ONO4538

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Maximum tolerated dose (MTD) of each combination (Phase I)
Prazo: 21 days

MTD defined as the highest dose level at which less than 33% of 6 patients experience a dose limiting toxicity, will be graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Upon completion of the trial, frequency of subjects experiencing toxicities will be tabulated. Toxicities will be assessed and graded according to CTCAE version 4.0 terminology. Exact 95% confidence intervals (CI) around the toxicity proportions will be calculated.

21 days
CR rate (Phase II)
Prazo: Up to 10 years

The analysis of CR between two arms will be performed using exact Cochran-Mantel-Haenszel (CMH) test stratifying on prior brentuximab vedotin (BV) (yes versus [vs.] no) and age (< 18 vs. >= 18). Multivariable logistic regression modeling will be used to adjust for the effect of any covariates that are associated with these categorical outcomes.

Up to 10 years

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Complete response (CR) rate (Phase I)
Prazo: Up to 3 years

Assessed using the Revised Response Criteria for Malignant Lymphoma and reported along with the 95% CI.

Up to 3 years
Partial response (PR) rate (Phase I)
Prazo: Up to 3 years

Assessed using the Revised Response Criteria for Malignant Lymphoma and reported along with the 95% CI.

Up to 3 years
Overall response rate (ORR) rate (Phase I)
Prazo: Up to 3 years

Assessed using the Revised Response Criteria for Malignant Lymphoma and reported along with the 95% CI.

Up to 3 years
Duration of response (DOR) (Phase I)
Prazo: From the documented beginning of response up to 3 years

DOR will be estimated using Kaplan-Meier methodology. Greenwood's formula will be used to calculate 95% CI for the Kaplan-Meier estimates. Descriptive statistics will be used to evaluate the DOR achieved with the protocol therapy and with the most recent prior systemic therapy.

From the documented beginning of response up to 3 years
Overall survival (OS) (Phase I)
Prazo: From the date of study entry up to 3 years

OS will be estimated using Kaplan-Meier methodology. Greenwood's formula will be used to calculate 95% CI for the Kaplan-Meier estimates.

From the date of study entry up to 3 years
Progression-free survival (PFS) (Phase I)
Prazo: From entry onto study up to 3 years

PFS will be estimated using Kaplan-Meier methodology. Greenwood's formula will be used to calculate 95% CI for the Kaplan-Meier estimates.

From entry onto study up to 3 years
ORR (Phase II)
Prazo: Up to 10 years

Assessed using Revised Response (Cheson) and Deauville criteria. The analysis of ORR between two arms will be performed using the CMH test stratifying on prior BV (yes vs. no) and age (< 18 vs. >= 18). Multivariable logistic regression modeling will be used to adjust for the effect of any covariates that are associated with these categorical outcomes.

Up to 10 years
PFS (or modified PFS) (Phase II)
Prazo: From randomization up to 10 years

PFS will be estimated using Kaplan-Meier methodology and compared between arms using stratified log-rank test. Greenwood's formula will be used to calculate 95% confidence intervals for the Kaplan-Meier estimates. Cox proportional regression model will be used to estimate hazard ratios (95% CI) and assess the relationship between other prognostic factors with time-to-event outcome. Point estimates of all endpoints will be accompanied by the corresponding 95% confidence intervals.

From randomization up to 10 years
OS (Phase II)
Prazo: From randomization up to 10 years

OS will be estimated using Kaplan-Meier methodology and compared between arms using stratified log-rank test. Greenwood's formula will be used to calculate 95% confidence intervals for the Kaplan-Meier estimates. Cox proportional regression model will be used to estimate hazard ratios (95% CI) and assess the relationship between other prognostic factors with time-to-event outcome. Point estimates of all endpoints will be accompanied by the corresponding 95% confidence intervals.

From randomization up to 10 years
DOR (Phase II)
Prazo: From the documented beginning of response up to 10 years

DOR, will be estimated using Kaplan-Meier methodology and compared between arms using stratified log-rank test. Greenwood's formula will be used to calculate 95% confidence intervals for the Kaplan-Meier estimates. Cox proportional regression model will be used to estimate hazard ratios (95% CI) and assess the relationship between other prognostic factors with time-to-event outcome. Point estimates of all endpoints will be accompanied by the corresponding 90% confidence intervals. The DOR achieved with the most recent prior systemic therapy will be collected on the case report forms, and descriptive statistics will be used to evaluate the DOR achieved with the protocol therapy and with the most recent prior systemic therapy.

From the documented beginning of response up to 10 years

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Efeitos de combinações na imunidade sistêmica (Fase I e II)
Prazo: Linha de base até 6 semanas após a conclusão do tratamento do estudo
Linha de base até 6 semanas após a conclusão do tratamento do estudo
Change in the percentage of activated T cells and natural killer cells (Phase I and II)
Prazo: Baseline (Time 1) to 9 weeks (Time 3, time of first re-staging)

These quantities of interest will be calculated for each patient and the Wilcoxon signed-rank test will be used to test for significant difference between the time points. Using Wilcoxon rank sum test (two-sided type I error of 0.1), differences between those who progress or die within one year versus (vs.) those who are event-free at one year will be evaluated.

Baseline (Time 1) to 9 weeks (Time 3, time of first re-staging)
Change in the percentages of activated T cells and natural killer cells (Phase I and II)
Prazo: Day 1 of cycle 2 (Time 2) or 9 weeks (Time 3) to up to 6 weeks after completion of study treatment (Time 4, end of study)

These quantities of interest will be calculated for each patient and the Wilcoxon signed-rank test will be used to test for significant difference between the time points. Using the Wilcoxon rank sum test (two-sided type I error of 0.1), differences between those who progress or die within one year vs. those who are event-free at one year will be evaluated.

Day 1 of cycle 2 (Time 2) or 9 weeks (Time 3) to up to 6 weeks after completion of study treatment (Time 4, end of study)
Pre- and post-treatment levels of cytokines and T cell specific biomarkers (Phase I and II)
Prazo: Baseline to up to 6 weeks after completion of study treatment

Pre- and post-treatment levels of these markers will be compared using the Wilcoxon signed-rank test with two-sided type I error of 0.1. Marker levels between patients who fail at 1-year vs. patients who are event-free at 1-year will be evaluated. Given limited data, the analyses of PD-1, co-expression of Tim-3 with PD-1, ICOS, sCD30, galectin-1 and the peripheral blood absolute lymphocyte to monocyte ratio will be mainly exploratory and will be summarized descriptively at the time-points described above. The association with PFS will be explored.

Baseline to up to 6 weeks after completion of study treatment
Differentially expressed genes between two groups (patients who fail at 1-year vs. patients who are event-free at 1-year or responders vs. non-responders) (Phase I and II)
Prazo: 1 year

Assessed using gene expression profiling (GEP). Differentially expressed genes will be identified using a rank-based method developed by Dr. Hong (RankProd, R package, Bioconductor Project) with multiple comparison adjustment using a false discovery rate approach. A two-way unsupervised hierarchical clustering analysis will be applied to both the genes and the samples to illustrate whether GEP can separate two groups or is associated with other clinical factors. The genes ranked as most significant will be assessed by gene ontology and pathway analysis for their potential functions in lymphoma biology and treatment failure.

1 year
Microbiome analysis (Phase I and II)
Prazo: Completion of study treatment

Will compare the gut microbiome between Hodgkin lymphoma (HL) patients and healthy controls with respect to global diversity, taxonomic abundance, and bacterial functional pathways. The relative abundance of each taxon (phyla to genera) and functional pathways among different groups will be statistically compared in univariate analysis using t-test (or Wilcoxon test) and in multivariate analysis using logistic regression. Global diversity tests and multivariate analysis for taxonomic abundance and functional pathways will be adjusted for potential confounders (age, sex, race, and body mass index) in the comparisons of HL patients and controls, and further adjusted for stage and grade when examining the clinical response among HL patients.

Completion of study treatment
Absolute maximum standard uptake value (SUVmax) (Phase II)
Prazo: Up to cycle 10

Image data will be evaluated using Lugano response criteria with various D 5PS cut-offs in the entire cohort and in different therapy cohorts to determine if the existing set of criteria is sufficient to segregate the group into various response categories. Will correlate PFS, event free survival (EFS), OS 5PS in two reading settings (1-3 [negative] vs 4-5 [positive] and D 5PS 1-4 [negative] vs 5 [positive]) (Kaplan-Meier [KM] curve and log-rank testing).

Up to cycle 10
Metabolic whole body tumor volume (MTV) and tumor lesion glycolysis (TLG)
Prazo: Up to cycle 10

Image data will be evaluated using Lugano response criteria with various D 5PS cut-offs in the entire cohort and in different therapy cohorts to determine if the existing set of criteria is sufficient to segregate the group into various response categories. Will correlate PFS, EFS, OS 5PS in two reading settings (1-3 [negative] vs 4-5 [positive] and D 5PS 1-4 [negative] vs 5 [positive]) (KM curve and log-rank testing).

Up to cycle 10
Percent change in SUVmax, MTV and TLG between baseline and during therapy
Prazo: Baseline up to cycle 10

Image data will be evaluated using Lugano response criteria with various D 5PS cut-offs in the entire cohort and in different therapy cohorts to determine if the existing set of criteria is sufficient to segregate the group into various response categories. Will correlate PFS, EFS, OS 5PS in two reading settings (1-3 [negative] vs 4-5 [positive] and D 5PS 1-4 [negative] vs 5 [positive]) (KM curve and log-rank testing).

Baseline up to cycle 10
Percent change in size (sum of perpendicular diameters [SPD]) on computed tomography (CT)
Prazo: Baseline up to cycle 10

Image data will be evaluated using Lugano response criteria with various D 5PS cut-offs in the entire cohort and in different therapy cohorts to determine if the existing set of criteria is sufficient to segregate the group into various response categories. Will correlate PFS, EFS, OS 5PS in two reading settings (1-3 [negative] vs 4-5 [positive] and D 5PS 1-4 [negative] vs 5 [positive]) (KM curve and log-rank testing).

Baseline up to cycle 10
Absolute CT tumor volumes
Prazo: Up to cycle 10

Image data will be evaluated using Lugano response criteria with various D 5PS cut-offs in the entire cohort and in different therapy cohorts to determine if the existing set of criteria is sufficient to segregate the group into various response categories. Will correlate PFS, EFS, OS 5PS in two reading settings (1-3 [negative] vs 4-5 [positive] and D 5PS 1-4 [negative] vs 5 [positive]) (KM curve and log-rank testing).

Up to cycle 10
Percent change in CT size (SPD) and in CT tumor volume between baseline and during therapy
Prazo: Baseline up to cycle 10

Image data will be evaluated using Lugano response criteria with various D 5PS cut-offs in the entire cohort and in different therapy cohorts to determine if the existing set of criteria is sufficient to segregate the group into various response categories. Will correlate PFS, EFS, OS 5PS in two reading settings (1-3 [negative] vs 4-5 [positive] and D 5PS 1-4 [negative] vs 5 [positive]) (KM curve and log-rank testing).

Baseline up to cycle 10

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Catherine S Diefenbach, ECOG-ACRIN Cancer Research Group

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

7 de março de 2014

Conclusão Primária (Estimado)

30 de junho de 2027

Conclusão do estudo (Estimado)

30 de junho de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

8 de julho de 2013

Enviado pela primeira vez que atendeu aos critérios de CQ

8 de julho de 2013

Primeira postagem (Estimado)

11 de julho de 2013

Atualizações de registro de estudo

Última Atualização Postada (Real)

12 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

11 de novembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever